Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. (Record no. 17002233)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02305 a2200625 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250515064601.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 200706s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1527-7755 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1200/JCO.2006.07.9525 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Moore, Malcolm J |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20070608 |
| 245 00 - TITLE STATEMENT | |
| Title | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Date of publication, distribution, etc. | May 2007 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1960-6 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adenocarcinoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | therapeutic use |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Deoxycytidine |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Double-Blind Method |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Erlotinib Hydrochloride |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | International Agencies |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pancreatic Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Placebos |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Prognosis |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Quinazolines |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Survival Rate |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Treatment Outcome |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gemcitabine |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Goldstein, David |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hamm, John |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Figer, Arie |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hecht, Joel R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gallinger, Steven |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Au, Heather J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Murawa, Pawel |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Walde, David |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wolff, Robert A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Campos, Daniel |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lim, Robert |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ding, Keyue |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Clark, Gary |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Voskoglou-Nomikos, Theodora |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ptasynski, Mieke |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Parulekar, Wendy |
| 773 0# - HOST ITEM ENTRY | |
| Title | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| Related parts | vol. 25 |
| -- | no. 15 |
| -- | p. 1960-6 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1200/JCO.2006.07.9525">https://doi.org/10.1200/JCO.2006.07.9525</a> |
| Public note | Available from publisher's website |
No items available.